Comparison Table: Some Drugs for Migraine Prevention (online only)

The Medical Letter on Drugs and Therapeutics

ONLINE
ONLY
ARTICLE

September 28, 2026

View Complete Issue Table of Contents 2019

PDF: US English

Disclosures & Objectives Disclosures & Objectives

Show Related Terms Hide Related Terms

View Complete Issue

Send Article Feedback

Disclosures

Principal Faculty

Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.

Additional Contributor(s)

Michael Viscusi, Pharm.D., Associate Editor has disclosed no relevant financial relationships.

Objective(s)

Upon completion of this activity, the participant will be able to:

Discuss the pharmacologic options available for preventive treatment of migraine and compare them based on their efficacy, dosage and administration, adverse effects, and drug interactions.
Determine the most appropriate treatment for prevention of migraine given the individual presentation of a patient.

Select a term to see related articles Aimovig Ajovy amitriptyline antiepileptics Atacand atogepant beta blockers Botox botulinum toxin candesartan Cymbalta Depakote duloxetine Effexor Emgality eptinezumab erenumab fremanezumab galcanezumab Lopressor metoprolol migraine nortriptyline Nurtec onabotulinumtoxinA propranolol Qulipta rimegepant SNRIs Topamax topiramate Toprol tricyclic antidepressants Trokendi valproate venlafaxine Vyepti

Med Lett Drugs Ther. 2026 Sep 28;68(1764):e159-61 doi:10.58347/tml.2026.1764d

View the Comparison Table: Some Drugs for Migraine Prevention
Download PDF: US English

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.